Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
4600 participants
OBSERVATIONAL
2016-06-30
2020-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This multicenter prospective cohort studies the efficiency and safety of TCM compared with antidepressants. A total number of 4600 cases with primary depression are expected to be collected and divided into 3 cohorts based on the patients' requirement and choices. Patients in one group will receive TCM, and patients in the other two groups will respectively receive antidepressants only and integrated treatment of TCM and antidepressants. This study has 2 phases: treating period and the follow-up.
The main purpose of this long-term study is to evaluate the efficiency of TCM compared with antidepressants in reducing relapse and suicide rate, changing lifestyle, improving patient compliance as well as the safety.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neurochemical, Metabonomics and Neuroimaging Characterization of TCM Diagnostic Subtypes of Major Depression Disorder
NCT02346682
Effectiveness of Acupuncture for Depressed Patients Not Taking Antidepressant Medications
NCT01634022
Depression Care Management for Depressed Elders in China Primary Care
NCT01287494
TCM Health Preservation for Depression
NCT05799586
Culturally Sensitive Collaborative Treatment for Depressed Chinese Americans
NCT00227929
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The main purpose of this study is to observe the differences between cohorts. However, the intra-group differences are also needed to be evaluated, as the therapies of different participants are various. Therefore, the number of participants treated with each therapy and the time of recovery need to be counted and analyzed. This is a long-term and natural study that participants lost, drug withdrawal and changes in participants'choices of the therapy cannot be avoided. So the reason and number of the previous conditions need to be observed. The safety of TCM and antidepressants is also a considerable outcome which will be evaluated by laboratory examination, Treatment Emergent Symptom Scale (TESS) and the number of participants with adverse events.
Some of the outcomes are measured by questionnaires which can be divided into two parts. One is self-rated assessments including Self-rating Depression Scale (SDS) and Self-reporting Inventory (SCL-90). The other one is evaluated by doctors, such as Hamilton Depression Rating Scale of 24 items (HAMD), Montgomery-Asberg Depression Rating Scale (MADRS), Social Disability Screening Schedule (SDSS), Mini-mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA)and Traditional Chinese Medicine syndrome score.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Traditional Chinese Medicine
Including Zishui Qinggan Yin,Xiaoyao San, Longdan Xiegan Tang, Guipi Decoction, Ningshen Dingzhi Wan, HuangLian-EJiao decoction and Jiaotai Wan.
Traditional Chinese Medicine
Participants are treated with TCM twice per day according to syndrome differentiation. For example, the syndrome of one participant with depression is kidney deficiency. He will take Zishui Qinggan Yin twice per day before the breakfast and dinner.
TCM plus antidepressants
This is a integrative therapy that refers to a new treating system including TCM and antidepressants.
Traditional Chinese Medicine
Participants are treated with TCM twice per day according to syndrome differentiation. For example, the syndrome of one participant with depression is kidney deficiency. He will take Zishui Qinggan Yin twice per day before the breakfast and dinner.
Antidepressants
Participants are treated with different antidepressants. The dosage, frequency and duration are determined according to guideline.
Antidepressants
Antidepressants include Selective serotonin reuptake inhibitors (SSRIs), Norepinephrine-reuptake inhibitors and other antidepressants, such as Paroxetine, Citalopram, Venlafaxine, Sertraline, Trazodone, Maprotiline and so on.
Antidepressants
Participants are treated with different antidepressants. The dosage, frequency and duration are determined according to guideline.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Traditional Chinese Medicine
Participants are treated with TCM twice per day according to syndrome differentiation. For example, the syndrome of one participant with depression is kidney deficiency. He will take Zishui Qinggan Yin twice per day before the breakfast and dinner.
Antidepressants
Participants are treated with different antidepressants. The dosage, frequency and duration are determined according to guideline.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinical diagnosis of depression
* The scores of Hamilton Depression scale ( HAMD )≥18
* With stable vital signs, conscious mind and acceptable communication ability
* Can use the mobile phone to do self-evaluation
* Male or female patients between 18 and 65 years old
* Signing the informed consent and agreeing to participate in this study
Exclusion Criteria
* Depression caused by other diseases
* Unstable vital signs
* Severe aphasia and agnosia causing disability to communicate
* Alcoholism and other substance dependence
* Diagnosis of other mental disorders except depression
* Serious hepatic or renal insufficiency
* Pregnancy or lactation
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
OTHER
Beijing HuiLongGuan Hospital
OTHER
The First Affiliated Hospital of Henan University of Traditional Chinese Medicine
OTHER
First Affiliated Hospital of Heilongjiang Chinese Medicine University
OTHER
The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine
OTHER
Shandong University of Traditional Chinese Medicine
OTHER
Capital Medical University
OTHER
Xiamen Hospital of Traditional Chinese Medicine
OTHER
Wu Xi Hospital of Traditional Chinese Medicine
UNKNOWN
The Third Affiliated Hospital of Beijing University of Chinese Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Qisheng Tang
MD, PHD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Qisheng Tang, MD, PHD
Role: STUDY_DIRECTOR
The Third Affiliated Hospital of Beijing University of Chinese Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Third Affiliated Hospital of Beijing University of Chinese Medicine
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
201507001-12
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.